Nature Reviews Cancer 'Under Consideration': What the Status Means

The first status period is not the full scientific review. It is the journal checking whether the record can be handled: files open correctly, author metadata is complete, disclosures are included, ethics statements are present, and the manuscript appears to match the journal's scope. For Nature Reviews Cancer, this stage matters because a small administrative issue can look like a peer-review delay from the author's side. If the status changes quickly to Under Consideration, read that as a routing signal, not as proof that every reviewer has accepted.

The useful action during this stage is not to ask whether the editor likes the paper. It is to make sure every status email, submission-form field, and manuscript file points to the same claim. A mismatch between the cover letter, abstract, figure sequence, and supplementary files creates editorial friction even when the work is credible. For Nature Reviews Cancer, the file package should make clear that the manuscript or proposal fits a Nature Reviews article type and makes a field-shaping oncology synthesis rather than presenting original research, case reports, meta-analysis, or a routine systematic review before a reviewer has to hunt for it.

At this point the manuscript is being read for fit. The editor is not only asking whether the manuscript is polished, but whether the manuscript or proposal fits a Nature Reviews article type and makes a field-shaping oncology synthesis rather than presenting original research, case reports, meta-analysis, or a routine systematic review. In commissioned and proposal-led oncology review, perspective, comment, and research-synthesis publishing, a manuscript can be technically careful and still difficult to route if the abstract promises one contribution while the methods, figures, theory, or supplementary files support another.

The editor may be matching the manuscript to oncology field reviewers, cancer-biology reviewers, translational-oncology reviewers, clinical-oncology reviewers, immuno-oncology reviewers, methods-aware review readers, and Nature Reviews editors. That matching process can take time because the editor needs reviewers who can evaluate the central claim without reconstructing the manuscript's logic from scratch. Under Consideration can therefore cover both reviewer recruitment and active review.

At Nature Reviews Cancer, the handling editor is usually making two decisions at once: whether the submission deserves outside assessment and which reviewer pool can test the manuscript fairly. Nature Reviews Cancer is a Nature Reviews journal, so Under Consideration often covers editorial assessment of fit, commissioning logic, article type, author team, scope, and whether the synthesis will serve a broad oncology readership. The handling editor is usually testing whether the topic should be invited, revised as a proposal, reviewed externally, transferred, or declined. That editorial culture matters because the status label can look static while the handling editor checks scope, article type, evidence traceability, conflicts, and reviewer availability. Authors should prepare for comments on article type, proposal synopsis, field map, novelty of synthesis, figure plan, author expertise, literature coverage, oncology breadth, and Nature Portfolio policy compliance while the handling editor is still shaping the review path.

In parallel, the editor may be identifying two or three reviewers and checking whether the manuscript has the right scope for those reviewers. Recruiting reviewers can take 7 to 21 days when the topic sits between fields, depends on a specialized dataset, or requires both methodological and domain expertise. A Nature Reviews Cancer manuscript can therefore show Under Consideration while the editor is still securing the right reviewer mix.

For authors, the useful question is not "has someone accepted yet?" The useful question is "if a reviewer accepts today, would the manuscript's article type, proposal synopsis, field map, novelty of synthesis, figure plan, author expertise, literature coverage, oncology breadth, and Nature Portfolio policy compliance make the claim easy to evaluate?" That is the difference between passive waiting and productive waiting.

This is the main period in which reviewers evaluate the paper. They are usually checking whether the conclusion follows from the methods, whether the strongest comparison or control is present, whether figures match claims, and whether limitations are honest. In Nature Reviews Cancer, the common weak point is not always the headline finding. It is often the missing bridge between the manuscript's strongest claim and the evidence a reviewer can audit quickly.

Active review is also where timeline anxiety becomes least informative. A quiet portal does not tell you whether one reviewer is late, whether the editor is waiting for a second report, whether a reviewer declined and had to be replaced, or whether reports are already in synthesis. The strongest response is to prepare the material you will need under every plausible decision path.

Use the waiting window to produce a revision-ready response map. Put the likely objection in one column, the manuscript location in another, the strongest supporting figure or table in a third, and the limitation language in a fourth. If the decision is revise, that map saves days. If the decision is reject, it helps you choose a cleaner transfer or resubmission path.

After reports arrive, the editor has to turn them into a decision. This can still look like Under Consideration, Reviews Complete, Required Reviews Complete, or Decision in Process depending on the portal. Do not assume silence during this period means rejection. It can mean the editor is reconciling mixed reports, checking whether one reviewer misunderstood the scope, or deciding whether the manuscript needs another opinion.

The synthesis window is where the editor tests whether the reviewer concerns are compatible. If one reviewer wants deeper methods and another wants a shorter argument, the decision letter may take longer because the editor has to decide which instruction governs the revision. That delay is procedural, not necessarily negative.

Not automatically. The most common explanation is reviewer recruitment or a delayed report, not a hidden rejection. The more useful interpretation is whether the elapsed time matches the stage. If the paper moved to Under Consideration quickly and then stayed there, the editor may still be waiting on one reviewer. If the status changed after several weeks, the editor may be synthesizing reports. If there has been no movement past 12 weeks, a polite inquiry is reasonable.

What you should not do is rewrite the manuscript in panic or submit elsewhere. Prepare the response materials that will matter if the decision is revise, reject with comments, or transfer.

Across our pre-submission review work with Nature Reviews Cancer manuscripts, three named status-risk patterns explain most of the productive work authors can do while the portal still says Under Consideration. These patterns are useful because they are tied to manuscript components a reviewer can inspect, not to generic advice about waiting.

In our pre-submission review work on Nature Reviews Cancer manuscript packages, each specific failure pattern below turns into a concrete status-window task: inspect the abstract, first figure or model, methods, cover letter, data files, reporting notes, and limitation language before the reviewer report arrives.

The pages that create the most avoidable status anxiety are not always the obviously weak papers. They are credible papers where authors wait passively during Under Consideration instead of preparing for the exact review objections most likely to arrive. Official guidance explains the workflow, but it rarely connects the status label to the manuscript components reviewers will test.

• Nature Reviews Cancer evidence-chain gap: The editor needs to see article type, proposal synopsis, field map, novelty of synthesis, figure plan, author expertise, literature coverage, oncology breadth, and Nature Portfolio policy compliance without piecing together the claim from scattered files. Prepare a one-page response map that ties the central claim to figures, methods, data files, theory, and limitations.

• Nature Reviews Cancer reviewer-routing risk: The wrong reviewer pool can make a sound paper look less convincing than it is. Use the waiting window to identify how the abstract, keywords, suggested reviewers, article type, and field framing point to oncology field reviewers, cancer-biology reviewers, translational-oncology reviewers, clinical-oncology reviewers, immuno-oncology reviewers, methods-aware review readers, and Nature Reviews editors.

• Nature Reviews Cancer source-to-claim friction: Reviewers move quickly from headline claim to evidence traceability. Check that the source data, repository links, supplementary files, figure legends, models, theory logic, and methods are easy to audit.

• Nature Reviews Cancer revision-readiness gap: Revision speed depends on whether authors already know which objection is likely. Draft answer blocks for the two most likely reviewer concerns before the decision letter arrives.

The recurring Manusights pattern is that authors often over-prepare the wrong asset while the manuscript is under review. They polish prose when the likely reviewer objection is a missing control, rewrite the introduction when the likely problem is a benchmark table, or wait for the decision letter when the abstract, methods, figures, theory, and supplementary files already reveal the response strategy. For Nature Reviews Cancer, the highest-value waiting work is to make the evidence chain explicit enough that a reviewer can test the claim without inventing the authors' logic.

Of the 100 most recent Manusights pre-submission reviews we use as a status-page pattern sample, the useful signal was not the portal label by itself. It was whether the draft already had a journal-specific evidence map before reports arrived. Official guidance explains the workflow, but that is why this page ties Under Consideration to article type, proposal synopsis, field map, novelty of synthesis, figure plan, author expertise, literature coverage, oncology breadth, and Nature Portfolio policy compliance instead of only defining the status phrase.

If you want a second set of eyes before the report lands, use the Nature Reviews Cancer AI review to identify reviewer-risk issues while the manuscript is still under consideration.

Nature Cancer, Cancer Cell, Clinical Cancer Research, Annals of Oncology, Cancer Discovery, Trends in Cancer, and Nature Reviews Clinical Oncology can be reasonable alternatives when the evidence package is strong but the editorial center of gravity does not match Nature Reviews Cancer. Do not treat transfer planning as pessimism. It is a way to shorten the next move if the decision letter confirms the current venue is one level too broad, too narrow, or too format-specific.

Source limitations: this page uses public official-source guidance plus Manusights manuscript-risk interpretation; it cannot see the private reviewer invitations, report status, or handling-editor notes inside your manuscript record.

Public journal guidance can tell you the portal, article-scope language, submission route, and broad peer-review policy. It usually cannot tell you whether your specific paper has reviewers assigned, whether a reviewer has missed a deadline, or whether the editor is leaning toward revision or rejection. That is why this page separates official-source facts from practical interpretation. The official sources anchor the workflow; the Manusights contribution is the manuscript-level risk translation.

Official sources used for this Under Consideration interpretation:

• https://www.nature.com/nrc/for-authors
• https://www.nature.com/nrc/editorial-policies
• https://support.nature.com/en/support/solutions/articles/6000214274-submitting-a-manuscript-to-a-journal
• https://support.nature.com/en/support/solutions/articles/6000229822-submission-and-peer-review-query-contact-instructions
• https://www.nature.com/nature-portfolio/for-authors/publish

Source-specific notes from this research pass:

• Nature Reviews Cancer author pages explain article preparation, submission, editorial process, and the relationship to other Nature Research journals.
• Nature support says Nature Portfolio manuscript submission uses the journal homepage submission links and the Editorial Manager peer-review system.
• Nature support directs peer-review and manuscript-under-review queries through the journal contact option on the relevant journal website.

• Nature Reviews Cancer hub
• Nature Reviews Cancer submission guide
• journal-selection guide
• not-ready warning signs
• cover-letter guide

Before you wait another month, run a Nature Reviews Cancer reviewer-risk check and prepare the revision map reviewers are most likely to force you to build later.